Event Date/Time: Jun 04, 2013 End Date/Time: Jun 06, 2013
Registration Date: Jun 06, 2013
Early Registration Date: Apr 19, 2013
Abstract Submission Date: Apr 19, 2013
Report as Spam


After a dozen years, covering various topics for the pharmaceutical industry, the World Pharma Congress has found its niche in effectively covering the latest preclinical strategies and technologies for driving better predictions. Building on its experience covering drug targets, high-throughput screening, lead optimization, ADME and drug safety, the event is now primed to move further downstream into early formulations and drug delivery.

Conference Programs:

  • Cancer Models -- Challenging Cancer Heterogeneity with Reproducible and Predictive Preclinical Studies 
  • Pain Therapeutics -- Translating Success from Preclinical Assays to the Clinic
  • Drug Delivery and Formulation -- Driving Innovation Through Effective Tools and Novel Drug Delivery Strategies
  • Predictive Drug Safety -- Predicting Drug-Induced Organ Toxicities Using Functional Assays, Models and Markers
  • Preclinical Imaging -- Integrating Molecular Imaging Technologies to Improve Preclinical Findings

Short Courses:

  • Addressing Safety Concerns for Biologics and Biosimilars
  • Utilization of Cardiac Contractility Assays for Preclinical Safety Testing
  • Animal Models of Pain: Progress and Challenges
  • Design and Interpretation of Stability Studies for Difficult Drugs
  • Use of Stem Cells for Safety Screening
  • Introduction to Drug Metabolism and Its Role in Drug Toxicity
  • Epigenetic Mechanisms of Pain
  • Development of Nanotechnology Application into Innovative Therapies
  • Roadmap for Outsourcing of Preclinical Imaging
  • Advances in Imaging Quantitation
  • Genetically Engineered Mouse Models versus Patient-Derived Xenograft Models: Comparing Strengths and Limitations
Register early for maximum savings!


1200 Market St
United States

Conference Speakers


Speakers Include:  
  • Kevin Webster, Ph.D., Vice President, Oncology Research, AstraZeneca
  • Eric Holland, M.D., Ph.D., Director, Brain Tumor Center; Vice Chair, Translational Research, Department of Surgery, Emily Tow Jackson Chair in Oncology, Memorial Sloan Kettering Cancer Center.
  • Terry A. Van Dyke, Ph.D., Head, Mouse Cancer Genetics Program; Program Director, Cancer Pathways and Mechanisms, National Cancer Institute
  • Norman M. Greenberg, Ph.D., Vice President, Research and Development, MedImmune
  • David Heimbrook, Ph.D., CEO, SAIC-Frederick National Laboratory for Cancer Research
  • David Sidransky, MD, Chairman & Co-Founder, Champions Oncology, Inc.
  • Karim Dabbagh, Ph.D., Executive Director and Head, External R&D and Innovation Research Units, Pfizer Worldwide R&D
  • Glen N. Gaulton, Ph.D., Professor, Pathology and Laboratory Medicine; Executive Vice Dean and CSO, Perelman School of Medicine, University of Pennsylvania
  • Peter Pitts, President and Co-Founder, Center for Medicine in the Public Interest
  • Dr. Andrew L. Kung, M.D., Ph.D., Director, Pediatric Hematology, Oncology and Stem Cell Transplantation, New York-Presbyterian Morgan Stanley Children’s Hospital/Columbia University Medical Center
  • Jeffrey E. Green, M.D. Head, Transgenic Oncogenesis and Genomics Section, Center for Cancer Research, National Cancer Institute
  • Glenn Merlino, Ph.D., Chief, Molecular Genetics Section, Laboratory of Molecular Biology, Division of Basic Science, National Cancer Institute
  • Henry Smilowitz, Ph.D., Associate Professor, Cell Biology, University of Connecticut Health Center
  • Celina D’Cruz, Ph.D., Principal Scientist I, Oncology Innovative Medicines, R&D, AstraZeneca
  • Dylan Daniel, Ph.D., Investigator III, Oncology Pharmacology, Novartis Institutes for Biomedical Research
  • Neal Goodwin, Ph.D., Director, Research and Development, In Vivo Pharmacology Services, The Jackson Laboratory
  • Martin Carroll, M.D., Associate Professor, Division of Hematology and Oncology, University of Pennsylvania School of Medicine
  • Hui Gao, Ph.D., Investigator III, Novartis Institutes for Biomedical Research
  • Tan A. Ince, M.D., Ph.D., Director, Tumor Stem Cell Division, Interdisciplinary Stem Cell Institute and Associate Professor of Pathology, Braman Family Breast Cancer Institute, Miller School of Medicine, University of Miami
  • Prem K. Premsrirut, Ph.D., CEO, Mirimus, Inc.
  • Andrew Rhim, M.D., Instructor of Medicine, Gastroenterology/Medicine, University of Pennsylvania
  • Peter King, Ph.D., Senior Scientist, Molecular Imaging (Oncology), Janssen, Pharmaceutical Companies of Johnson and Johnson
  • Charles Glaus, Ph.D., Scientist, Research Imaging Sciences, Amgen
  • Werner Scheuer, Research Leader, Pharma Research and Early Development, Discovery Oncology; Roche Diagnostics GmbH
  • Willem Mulder, Ph.D., Associate Professor of Radiology, Director, Nanomedicine Program, Translational and Molecular Imaging Institute, Mount Sinai School of Medicine
  • Theresa Zhang, Ph.D., Associate Director, Merck Research Laboratories
  • Darrin Stuart, Senior Research Investigator II, Novartis Institutes for Biomedical Research
  • Erica Jackson, Ph.D., Scientist, Research Group Leader, Genentech
  • Chandan Kumar-Sinha, Ph.D., Research Assistant Professor, Pathology, University of Michigan

For a complete list of speakers and presentations, please visit the conference website.

Exhibits included

For sponsorship and exhibit information, please visit the conference website.